Increase of macrophage migration inhibitory factor (MIF) expression in cardiomyocytes during chronic hypoxia

Clinica Chimica Acta

Volumn 405, Issue 1-2, 2009, Pages 132-138

  Jian, Zhao ^a   Li, Jia Bei ^a   Ma, Rui Yan ^a   Chen, Lin ^a   Zhong, Qian Jin ^a   Wang, Xue Feng ^a   Wang, Wei ^a   Hong, Yi ^a   Xiao, Ying Bin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

5 adenosine monophosphate activated protein kinase (AMPK); Chronic hypoxia; Cyanotic heart defects; Macrophage migration inhibitory factor (MIF); Metabolic adaptation

Indexed keywords

ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANOXIA; CELL LINE; CHRONIC DISEASE; GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; INFANT; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASES; RATS;

RATTUS;

EID: 67349161511     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.04.016     Document Type: Article

References (57)

1. Kornosky J.L., and Salihu H.M. Getting to the heart of the matter: epidemiology of cyanotic heart defects. Pediatr Cardiol 29 (2008) 484-497
2. Arad M., Seidman C.E., and Seidman J.G. AMP-activated protein kinase in the heart role during health and disease. Circ Res 100 (2007) 474-488
3. Najm H.K., Wallen W.J., Belanger M.P., et al. Does the degree of cyanosis affect myocardial adenosine triphosohate levels and function in children undergoing surgical procedures for congenital heart disease?. J Thorac Cardiovasc Surg 119 (2000) 515-524
4. Imura H., Caputo M., Parry A., Pawade A., Angelini G.D., and Suleiman M.S. Age-dependent and hypoxia-related differences in myocardial protection during pediatric open heart surgery. Circulation 103 (2001) 551-556
5. Wittmich C., and Torrance S.M. Does the severity of acute hypoxia influence neonatal myocardial metabolism and sensitivity to ischemia?. J Mol Cell Cardiol 26 (1994) 675-682
6. Young L.K., Li J., Baron S.J., and Russell R.R. AMP-activated protein kinase: a key stress pathway in the heart. Trends Cardiovasc Med 15 (2005) 110-118
7. Hardie D.G. AMP-activated/SNF 1 protein kinase: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8 (2007) 774-785
8. Russell III R.R., Li J., Coven D.L., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114 (2004) 495-503
9. Marsin A.S., Bouzin C., Bertrand L., and Hue L. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J Biol Chem 277 (2002) 30778-30783
10. Yun H., Lee M., Kim S.S., and Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Bio Chem 280 (2005) 9963-9972
11. Terai K., Hiramoto Y., Masaki M., et al. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 25 (2005) 9554-9575
12. Borger D.R., Gavrilescu L.C., Bucur M.C., Ivan M., and Decaprio J.A. AMP-activated kinase is essential for survival in chronic hypoxia. Biochem Biophys Res Commun 370 (2008) 230-234
13. Bernhagen J., Calandra T., and Bucala R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J Mol Med 76 (1998) 151-161
14. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 56 (1996) 72-77
15. Bernhagen J., Calandra T., Mitchell R.A., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 21 (1993) 756-759
16. Calandra T., and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3 (2003) 791-800
17. Zernecke A., Bernhgen J., and Weber C. Macrophage migration inhibitory factor in cardiovascular system. Circulation 117 (2008) 1594-1602
18. Lin S.G., Yu X.Y., Chen Y.X., et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 87 (2000) 1202-1208
19. Yu C.M., Lai K.W., Chen Y.X., Huang X.R., and Lan H.Y. Expression of macrophage migration inhibitory factor in acute ischemic myocardial injury. J Histochem Cytochem 51 (2003) 625-631
20. Miller E.J., Li J., Leng L., et al. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 451 (2008) 578-582
21. Landree L.E., Hanlon A.L., Atrong D.W., et al. C75, a fatty Acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism. J Biol Chem 279 (2004) 3817-3827
22. Takahashi M., Nishihira J., Shimpo M., et al. Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 52 (2001) 438-445
23. Frederich M., Zhang L., and Balschi J.A. Hypoxia and AMP independently regulate AMP-activated protein kinase activity in heart. Am J Physiol Heart Circ Physiol 288 (2005) H2412-H2421
24. Bonerva R.S., Botto L.D., Moore C.A., Yang Q., Correa A., and Erickson J.D. Mortality associated with congenital heart defects in the United States: trends and racial disparities, 1979-1997. Circulation 103 (2001) 2376-2381
25. Driscoll D.J. Evaluation of the cyanotic newborn. Pediatr Clin North Am 37 (1990) 1-23
26. Wittnich C., Torrance S.M., and Carlyle C.E. Effects of hyperoxia on neonatal myocardial energy status and response to global ischemia. Ann Thrac Surg 70 (2000) 2125-2131
27. Corno A.F., Milano G., Samaja M., Tozzi P., and von Segesser L.K. Chronic hypoxia: A model for cyanotic congenital heart defects. J Thorac Cardiovasc Surg 124 (2002) 105-112
28. van der Kuip M., Hoos M.B., Forget P.P., Westerterp K.R., Gemke R.J., and de Meer K. Energy expenditure in infants with congenital heart disease, including a meta-analysis. Acta Paediatr 92 (2003) 921-927
29. Chi N.C., and Karliner J.S. Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors. Cardiovasc Res 61 (2004) 437-447
30. Shibata R., Sato K., Pimentel D.R., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11 (2005) 1096-1103
31. Young L.H. AMP-activated protein kinase conducts the ischemic stress response orchestra. Circulation 117 (2008) 832-840
32. Calandra T., Bernhagen J., Mitchell R.A., and Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179 (1994) 1895-1902
33. Nishihira J., Koyama Y., and Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 10 (1998) 199-205
34. Bacher M., Meinhardt A., Lan H.Y., et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150 (1997) 235-246
35. Bernhagen J., Krohn R., Lue H., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13 (2007) 587-596
36. Ward M.R., Pasterkamp G., Yeung A.C., and Borst C. Arterial remodeling: mechanisms and clinical implication. Circulation 102 (2000) 1186-1191
37. Schober A., Bernhagen J., Thiele M., et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109 (2004) 380-385
38. Pan J.H., Lindholt J.S., Sukhova G.K., et al. Macrophage migration inhibitory factor is associated with aneurysmal expansion. J Vasc Surg 37 (2003) 628-635
39. Verschuren L., Lindeman J.H., van Bockel J.H., Abdul-Hussien H., Kooistra T., and Kleemann R. Up-regulation and coexpression of MIF and matrix metalloproteinases in human abdominal aortic aneurysms. Antioxid Redox Signal 7 (2005) 1195-1202
40. Dhanantwari P., Nadaraj S., Kenessey A., et al. Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochem Biophys Res Commun 371 (2008) 298-303
41. Garner L.B., Willis M.S., Carlson D.L., et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 285 (2003) H2500-H2509
42. Sakuragi T., Lin X., Metz C.N., et al. Lung-derived macrophage migration inhibitory factor in sepsis induces cardio-circulatory depression. Surg Infect (Larchmt) 8 (2007) 29-40
43. de Mendonca-Filho H.T., Pereira K.C., Fontes M., et al. Circulating inflammatory mediators and organ dysfunction after cardiovascular surgery with cardiopulmonary bypass: a prospective observational study. Crit Care 10 (2006) R46
44. Larson D.F., and Horak K. Macrophage migration inhibitory factor: controller of systemic inflammation. Crit Care 10 (2006) 138
45. Benigni F., Atsumi T., Calandra T., et al. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 106 (2000) 1291-1300
46. Atsumi T., Cho Y.R., Leng L., et al. The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol 179 (2007) 5399-5406
47. Hardie D.G., and Carling D. The AMP-activated protein kinase - fuel gauge of the mammalian cell?. Eur J Biochem 246 (1997) 259-273
48. Dyck J.R., and Lopaschuk G.D. AMPK alterations in cardiac physiology and pathology: enemy or ally?. J Physiol 574 (2006) 95-112
49. Kudo N., Gillespie J.G., Kung L., et al. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1301 (1996) 67-75
50. Beauloye C., Marsin A.S., Bertrand L., Vanoverschelde J.L., Rider M.H., and Hue L. The stimulation of heart glycolysis by increased workload does not require AMP-activated protein kinase but a wortmannin-sensitive mechanism. FEBS Lett 531 (2002) 324-328
51. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., and Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279 (2004) 32771-32779
52. Shibata R., Ouchi N., Ito M., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10 (2004) 1384-1389
53. Baron S.J., Li J., Russull III R.R., Neumann D., Miller E.J., and Tuerk R. Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circ Res 96 (2005) 337-345
54. Sakamoto K., Zarrinpashneh E., Budas G.R., et al. Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKα2 but not AMPKα1. Am J Physiol Endocrinol Metab 290 (2006) E780-E788
55. 2+/calmodulin-dependent protein kinase kinase beta. J Biol Chem 273 (1998) 31880-31889
56. Altarejos J.Y., Taniguchi M., Clanachan A.S., and Lopaschuk G.D. Myocardial ischemia differentially regulates LKB1 and an alternate 5′-AMP-activated protein kinase kinase. J Biol Chem 280 (2005) 183-190
57. Chan A.Y., and Dyck J.R. Activation of AMP-activated protein kinase (AMPK) inhibits protein synthesis: a potential strategy to prevent the development of cardiac hypertrophy. Can J Physiol Pharmacol 83 (2005) 24-28